Lexeo Therapeutics' Gene Therapy LX2020 Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation

Lexeo Therapeutics announced that its investigational gene therapy, LX2020, for PKP2 arrhythmogenic cardiomyopathy, has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA. This designation follows interim clinical data from the ongoing HEROIC-PKP2 phase I/II trial and strengthens its regulatory position.